Next Science (ASX:NXS) - Managing Director, Judith Mitchell
Managing Director, Judith Mitchell
Source: Next Science
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Next Science (NXS) has received CE Mark approval for its BlastX product
  • This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom
  • BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing
  • It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores
  • Next Science has ended the day 9.7 per cent in the green with shares trading at $1.30

Next Science (NXS) has received CE Mark approval for its BlastX product.

This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom.

Additionally, this approval is the second for the company, having received CE Mark approval for its Bactisure Surgical Lavage Product in March.

BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing.

It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores. It also prevents infections in acute wounds and surgical wounds.

Wounds such as these are difficult to treat, cause a decline in quality of life, and increase mortality, pain, and suffering.

A study completed in Texas showed that combining BlastX with custom antibiotics increased chronic wound closures by 40 per cent in a four-week randomised controlled trial.

“The receipt of a CE Mark approval for BlastX represents the successful conclusion of three years of work and marks a major milestone for Next Science as we pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health,” Managing Director Judith Mitchell said.

“The CE Mark is a minimum requirement for many other jurisdictions so we can now work on further approvals,” she added.

Next Science has ended the day 9.7 per cent in the green, with shares trading at $1.30 in a $230.1 million market cap.

NXS by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…